Database→FGL

Tier 3CognitiveNeuroprotectionNeurodegenerativePREMIUM

FGL

FGL (FG Loop) -- NCAM-Derived FGFR1 Agonist, 15-Amino Acid Neural Cell Adhesion Molecule Mimetic

Research compound. No FDA approval, no active IND, no patient-level efficacy trials registered or published. One completed Phase 1 PK/safety study in healthy volunteers (Anand et al., 2007). NeuroFGL clinical program (Enkam Pharmaceuticals, EU-funded 2012) announced but produced no published results. Not on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

FGL is a synthetic 15-amino acid peptide derived from the FG loop region of the second fibronectin type III module of NCAM (neural cell adhesion molecule). It acts as a selective FGFR1 agonist, promoting synaptogenesis, LTP, neurogenesis, and neuroprotection in preclinical models. A Phase 1 study in 24 healthy males confirmed tolerability and CNS penetration via intranasal administration. No efficacy trials in patients have produced published results despite a funded clinical program announced in 2012.

🔒

Full Profile: Premium Members Only

The complete FGL profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use